Skip to main content
OpenTrials
Completed

NCT Number: NCT01757483

Canadian Ticagrelor Survey

This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug interactions) and ASA dosage.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Montreal, Quebec, Canada

About this study

Effectiveness of risk minimisation interventions for ticagrelor in Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • N/A (All prescribers will be contacted for participation)

Exclusion criteria

  • Participation in a previous wave of the survey.

Treatment and study plan

Primary outcomes

  1. KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)

    Time frame: 2 months

Secondary outcomes

  1. KAU Questionnaire: Practice characteristics

    Time frame: 2 months

  2. KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns

    Time frame: 2 months

  3. KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.

    Time frame: 2 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Dec 31, 2012
Registry last updated
Dec 9, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.